Skip to main content
SpringerLink
Log in

FIRE-4.5-Studie

  • Sektion B
  • Published:
Forum Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Loupakis F et al (2014) Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371(17):1609–1618

    Article  PubMed  Google Scholar 

  2. Stintzing S et al (2016) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol :

    Google Scholar 

  3. Venook AP et al (2014) CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 32(suppl; abstr LBA3): (5 s)

    Google Scholar 

  4. Van Cutsem E et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27(8):1386–1422

    Article  PubMed  Google Scholar 

  5. Cremolini C et al (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol :

    Google Scholar 

  6. Bokemeyer C et al (2012) Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48(10):1466–1475

    Article  CAS  PubMed  Google Scholar 

  7. Stintzing S et al (2016) BRAF mutant and RAS mutant patients treated with FOLFIRI plus Bevacizumab or FOLFIRI plus Cetuximab. Role of ETS and molecular markers in FIRE-3 (AIO KRK-0306). Ann Oncol 27(Supplement S2):ii118–ii128

    Google Scholar 

  8. Pietrantonio F et al (2015) Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 51(5):587–594

    Article  CAS  PubMed  Google Scholar 

  9. Rowland A et al (2015) Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 112(12):1888–1894

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kopetz S et al (2015) Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol :

    Google Scholar 

  11. Atreya C et al (2015) Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). J Clin Oncol 33(suppl; abstr 103): (2016)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik mit Poliklinik III, Klinikum der Universität München (LMU), Marchioninistrasse 15, 81377, München, Deutschland

    Sebastian Stintzing

Authors
  1. Sebastian Stintzing
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sebastian Stintzing.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stintzing, S. FIRE-4.5-Studie. Forum 32, 54–56 (2017). https://doi.org/10.1007/s12312-016-0186-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12312-016-0186-6

Search

Navigation